Table 4 –
24-hr Hemodynamic Parameters of TG and ETB-def before and after A-192621
| TG Controls (n = 7) | ETB-def (n = 6) | ||||||
|---|---|---|---|---|---|---|---|
| Baseline | A-192621 | Baseline | A-192621 | 2-Way RM ANOVA (p) | |||
| SBP (mmHg) | 130.5 ± 1.7 | 148.5 ± 2.3**** | 150.0 ± 2.5#### | 150.1 ± 2.7 | Tx = 0.0002 | G = 0.0030 | Tx*G = 0.0002 |
| MAP (mmHg) | 107.6 ± 1.5 | 122.8 ± 2.0**** | 125.3 ± 2.6#### | 125.9 ± 2.9 | Tx = 0.0006 | G = 0.0044 | Tx*G = 0.0003 |
| DBP (mmHg) | 88.5 ± 1.4 | 102.1 ± 1.9**** | 103.6 ± 2.7### | 103.0 ± 3.3 | Tx = 0.0010 | G = 0.0206 | Tx*G = 0.0005 |
| HR (bpm) | 362.9 ± 4.5 | 325.9 ± 4.8**** | 365.9 ± 6.8 | 359.9 ± 12.2## | Tx = 0.0001 | G = 0.0827 | Tx*G = 0.0015 |
SBP: systolic blood pressure, MAP: mean arterial pressure, DBP: diastolic blood pressure, HR: heart rate, G: genotype, Tx: treatment with A-192621. 2-way Repeated Measures ANOVA with Sidak’s post-hoc test for multiple comparisons:
****,
p < 0.0001 vs. baseline;
##,
p < 0.01 vs. TG,
###,
p < 0.001 vs. TG
####,
p < 0.0001 vs. TG Mean ± SEM.
Group effect significance indicated by italics.